# IRADIMED share price today (IRADIMED CORPORATION, IRMD)

> IRADIMED CORPORATION's P/E is near the low end of its own history, higher than only 10% of past readings, and its quarterly results are still getting worse. IRMD · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/irmd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: $81.11 (+5.6% in a year)
- P/E: 43.4× (lower than 90% of the last 1 year)
- Revenue (Jun 2026): $20.5 M (+0.3% on a year ago)
- Profit (Jun 2026): $5.2 M (−9.6% on a year ago)
- Operating margin: 31.2% (−2.1 points on a year ago)
- ROE: 24%, FY25
- ROIC: 51.8%, against a 9.4% cost of capital: +42.4 points

The main question: the P/E is near the low end of its own history, higher than only 10% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. ## What is the IRADIMED share price today? IRADIMED CORPORATION's share price was $81.11 at the close on 3 November 2026. That is 12.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $77 and $104, and at that close it sat 16% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 13 weeks running. Over the last 1 year the share price moved +41% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 7 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does IRADIMED pay? IRADIMED CORPORATION paid $0.77 per share over the last four reported quarters. The most recent declaration was $0.20 for Jun 2026. At today's price of $81.11 that is a yield of 0.95%, based on dividends already paid, not a forecast. ## Which stock lists is IRADIMED on? IRADIMED is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is IRADIMED profitable? IRADIMED CORPORATION earned $5.2 M of net profit in the Jun 2026 quarter, −9.6% on the same quarter a year earlier. Full-year FY25 profit was $22.5 M. Over 4 years profit has grown 24.6% a year on average. That is 25.5% of the quarter's revenue. The same quarter a year earlier earned $5.8 M. For the full year, FY25 profit was $22.5 M (+16.9% on the year before). Why profit moved: revenue changed +0.3% on a year earlier and the margin moved −2.1 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +12.6% and revenue +11.4%. Profit and revenue are moving at about the same pace. ## How much revenue does IRADIMED make, and is it growing? IRADIMED CORPORATION reported $20.5 M of revenue in the Jun 2026 quarter, +0.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 19.0% a year on average. The last full year, FY25, came in at $83.8 M. The last four reported quarters add to $86.3 M. FY25 revenue was $83.8 M, +14.4% on the year before. Recent pace: the last four quarters grew +11.4% on average, against 19.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.2%, against +11.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +11.6%, against +11.2% a year (stabilising). ## How much of every $100 of sales does IRADIMED keep? IRADIMED CORPORATION's operating margin was 31.2% in the Jun 2026 quarter, 2.1 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 23.5% and 31.2%. The latest quarter is within that range. Across 5 years it has been between 23.5% and 31.2%, and FY25's 31.2% is the highest of them. Why the margin moved: operating margin changed −2.1 percentage points on the year while gross margin changed −4.1 points. So the drop came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is IRADIMED's profit turning into cash? Over the last 3 years, 109% of IRADIMED CORPORATION's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $24.9 M of operating cash against $22.5 M of profit. After $7.8 M of spending on assets, $17.2 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does IRADIMED's cash go? IRADIMED CORPORATION does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $23.2 M on assets over the last 3 years. Averaged over those years that is 9.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $23.2 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is IRADIMED's P/E ratio, and how does it compare with its own history? IRADIMED CORPORATION's P/E is 43.4×, near the low end of its own history: it has been lower only 10% of the time. Its usual P/E (the middle reading) is 49.9×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +16.7% while the price moved +5.6%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the IRADIMED business getting better or worse? IRADIMED CORPORATION's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 27.1%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## How much does IRADIMED earn on its capital? IRADIMED CORPORATION earned a ROE of 24% in FY25. That is up from a low of 13% in FY21. Its return on capital used (ROIC) is 42.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 26.8% net margin and 0.77× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 26.8% net margin × 0.77× asset turnover × 1.15× leverage (assets divided by equity) ≈ 23.7% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 51.8% − 9.4% = +42.4 percentage points. The 9.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 51.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 53.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does IRADIMED have too much debt? IRADIMED CORPORATION has total debt of $59.0 K against shareholder equity of $90.1 M as of Mar 2025, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.00 in FY24. So the returns on this page come from the business, not from borrowed money. ## What is the IRADIMED shareholding pattern? 8.0% of IRADIMED CORPORATION's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is IRADIMED from balance-sheet trouble? For IRADIMED CORPORATION, the Z-score is 51.16. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 51.16 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does IRADIMED rank in its industry? There is no score against its industry: IRADIMED CORPORATION is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is IRADIMED compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to IRADIMED in size? IRADIMED is the 41st largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Lumexa Imaging Holdings, Inc., SI-BONE, Inc. and Integra LifeSciences Holdings Corporation. Just below it: QuidelOrtho Corporation, Bioventus Inc. and AdaptHealth Corp. ### Medical Devices companies close in size

1. [Lumexa Imaging Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lmri) $1.1 billion
2. [SI-BONE, Inc.](https://www.sectoralpha.in/us/stocks/sibn) $1.1 billion
3. [Integra LifeSciences Holdings Corporation](https://www.sectoralpha.in/us/stocks/iart) $1.1 billion
4. IRADIMED CORPORATION $1 billion
5. [QuidelOrtho Corporation](https://www.sectoralpha.in/us/stocks/qdel) $966 million
6. [Bioventus Inc.](https://www.sectoralpha.in/us/stocks/bvs) $920 million
7. [AdaptHealth Corp.](https://www.sectoralpha.in/us/stocks/ahco) $838 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Digital Turbine, Inc.](https://www.sectoralpha.in/us/stocks/apps) $1 billion · Software - Application
2. [Standard Motor Products, Inc.](https://www.sectoralpha.in/us/stocks/smp) $1 billion · Auto Parts
3. IRADIMED CORPORATION $1 billion
4. [Universal Corporation](https://www.sectoralpha.in/us/stocks/uvv) $1 billion · Tobacco
5. [FMC Corporation](https://www.sectoralpha.in/us/stocks/fmc) $1 billion · Agricultural Inputs

## What else do people ask about IRADIMED? ### What were IRADIMED's latest quarterly results? IRADIMED CORPORATION reported revenue of $20.5 M and net profit of $5.2 M for the Jun 2026 quarter. Revenue rose 0.3% and profit fell 9.6% compared with a year earlier. Earnings per share were $0.41. The operating margin was 31.2%, 2.1 percentage points lower than a year earlier (as of 3 November 2026). ### What is IRADIMED's market cap? IRADIMED CORPORATION's market capitalisation is $1.0 B at a stock price of $81.11. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is IRADIMED performing? IRADIMED CORPORATION's latest readings are below. In its latest quarter, revenue rose 0.3% and profit fell 9.6% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 13 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will IRADIMED's stock price go up? This page does not forecast IRADIMED CORPORATION's stock price. What it shows instead: the stock price is $81.11. Its P/E of 43.4× is higher than 10% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is IRADIMED in its business cycle? IRADIMED CORPORATION's FY25 operating margin was 31.2%, against a 5-year range of 23.5% to 31.2%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 31.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the IRADIMED story? The main question: the P/E is near the low end of its own history, higher than only 10% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is IRADIMED a stock worth studying right now? What the numbers show: IRADIMED CORPORATION's P/E is near the low end of its own history, higher than only 10% of past readings, and its quarterly results are still getting worse. The main open question: whether results start to improve. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.